Approval for the watchman laa closure technology. this device is indicated to reduce the risk of thromboembolism from the left atrial appendage (laa) in patients with non-valvular atrial fibrillation who: are at increased risk for stroke and systemic embolism based on chads2 or cha2ds2-vasc scores and are recommended for anticoagulation therapy;  are deemed by their physicians to be suitable for warfarin; and have an appropriate rationale to seek a non-pharmacologic alternative to warfarin, taking into account the safety and effectiveness of the device compared to warfarin.